Trastuzumab News and Research

RSS
KU Cancer Center launches clinical trial to eliminate radiation therapy for HER2-positive breast cancer

KU Cancer Center launches clinical trial to eliminate radiation therapy for HER2-positive breast cancer

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Breast cancer drug can accelerate growth of tumors, shows research

Breast cancer drug can accelerate growth of tumors, shows research

Treating metastatic breast cancer with immunotherapy

Treating metastatic breast cancer with immunotherapy

New drugs and screening techniques reduce breast cancer mortality rates, research shows

New drugs and screening techniques reduce breast cancer mortality rates, research shows

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

Rogue messengers can negatively affect the body's immune system response against cancer

Rogue messengers can negatively affect the body's immune system response against cancer

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

Adding a second HER2-targeted treatment may improve outcomes for some women with breast cancer

Adding a second HER2-targeted treatment may improve outcomes for some women with breast cancer

WHO to launch pilot project for prequalifying biosimilar cancer medicines

WHO to launch pilot project for prequalifying biosimilar cancer medicines

Scientists identify biomarkers to predict patient’s response to breast cancer treatment

Scientists identify biomarkers to predict patient’s response to breast cancer treatment

Brain metastasis persists in women with HER2-positive breast cancer despite new targeted therapies

Brain metastasis persists in women with HER2-positive breast cancer despite new targeted therapies

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Treatment with biosimilar drug improves progression-free survival in breast cancer patients

New guidelines provide recommendations on HER2 testing for patients with gastroesophageal cancers

New guidelines provide recommendations on HER2 testing for patients with gastroesophageal cancers

Researchers identify new strategy to selectively sensitize cancer cells to radiation therapy

Researchers identify new strategy to selectively sensitize cancer cells to radiation therapy

Genetic testing of mtDNA may reveal unknown ancestry that influences risk for breast cancer

Genetic testing of mtDNA may reveal unknown ancestry that influences risk for breast cancer

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

Researchers uncover one way breast cancer tumors resist vital medication

Researchers uncover one way breast cancer tumors resist vital medication

Updated guidelines for breast cancer increase number of patients who test HER2-positive

Updated guidelines for breast cancer increase number of patients who test HER2-positive

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.